Collaborative Drug Discovery Integrates CDD Vault with NVIDIA BioNeMo NIM For AlphaFold2 and DiffDock Models
BURLINGAME, CA, UNITED STATES, April 2, 2025 / EINPresswire.com / -- Collaborative Drug Discovery, Inc. (CDD) announces the integration of NVIDIA BioNeMo NIM microservices for AlphaFold2 and DiffDock models into CDD Vault. This integration enriches experimental data within CDD Vault, a single, intuitive web-based platform, by incorporating predictive, industry-leading models. Researchers can manage, analyze, and securely collaborate on the integrated data with enhanced models, unlocking deeper insights and enabling more informed decision-making.
Scientists engaged in both commercial and humanitarian drug discovery have demonstrated that the integration with BioNeMo NIM for AlphaFold2 and DiffDock significantly enhances CDD Vault's existing AI module. These models are a powerful addition to CDD's chemistry-aware bioisosteric generation for novel structures (IP) and ultrafast deep-learning similarity capabilities. Chemists and biologists can now combine the best of their intuition with generative capabilities for small molecules visualized together with biological proteins.
NVIDIA NIM is a set of easy-to-use microservices designed to accelerate the deployment of generative AI models across the cloud, data center, and workstations. NIM microservices are categorized by model family and on a per-model basis.
'We wanted to give the 690+ research labs that are using CDD Vault effortless access to the powerful BioNeMo NIM tools, enabling them to seamlessly combine over 4 billion experimental data points and 80 million structures with AI-driven insights from these models,' said CDD Cheminformatician and Research Informatics Senior Scientist Dr. Peter Gedeck.
Collaborative Drug Discovery empowers CDD Vault users with access to powerful NVIDIA AI tools, BioNeMo NIM for AlphaFold2, a deep learning model that accelerates protein structure determination, and DiffDock, which predicts the 3D orientation and docking interactions of small molecules with proteins. These advanced tools provide a comprehensive structure-based drug discovery (SBDD) extension, enhancing the traditional capabilities of the CDD Vault scientific informatics platform.
'CDD Vault's strength is biological and chemical activity data management,' said Barry Bunin, CEO and Founder of Collaborative Drug Discovery. 'With our ELN (electronic laboratory notebook), Inventory, Curves, Automation, and AI modules, it was natural for us to collaborate with NVIDIA, the leading company for biological modeling. Our customers, some of whom are already using AlphaFold2 and DiffDock, are excited to have access to the NIM for these models, to support seamlessly integrating with CDD Vault, and more quickly move to deployment.'
'The ability to model biology and generate new chemical structures with AI is a profound breakthrough transforming the healthcare and life sciences space,' said Janet Paulsen, Senior Alliance Manager, Drug Discovery, NVIDIA. 'The integration of NVIDIA BioNeMo NIM microservices into CDD's Vault platform equips researchers on the forefront of this innovation with the advanced AI tools needed to harness data that can unlock biological insights.'
About Collaborative Drug Discovery (CDD)
CDD's ( www.collaborativedrug.com) flagship product, CDD Vault®, is a premier hosted database solution for the secure management and sharing of biological and chemical research data. CDD Vault® provides tools for managing chemical and biological registrations, structure-activity relationships (SAR), and organizing experiments. The platform's available modules include Registration, Activity, Visualization, Assays, ELN, Inventory, Curves, AI, and Automation.
Abraham Wang
+1 650 242 5259
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Watch These Broadcom Stock Price Levels After Post-Earnings Slide
Broadcom shares fell sharply Friday, one day after the chip giant delivered results and an outlook that were largely in line with Wall Street estimates. Profit-taking had crept into the stock Thursday on the highest volume in around two months after the stock hit a record high this week, setting the stage for today's selling. The relative strength index recently climbed above 80, a reading that coincided with major tops in the stock in December and June last year. Investors should watch key support levels on Broadcom's chart around $235 and $200, while also monitoring an important overhead area near $ (AVGO) shares fell sharply Friday, one day after the chip giant delivered results and an outlook that were largely in line with Wall Street estimates. The company's shares hit a fresh record high this week ahead of its highly anticipated results, boosted by expectations of robust revenue growth driven by surging demand for chips that power generative AI technology. CEO Hock Tan told analysts on the company's earnings call that chip demand may accelerate during the second half of 2026 due to strong inference demand, referring to the process that uses a trained AI model to make predictions or decisions. Still, Broadcom shares fell 5% to around $247 on Friday as the results and outlook may have missed the lofty expectations of investors, especially after the blockbuster results delivered by rival Nvidia last week. With today's decline, Broadcom shares are up about 6% since the start of the year, slightly outpacing the performance of the S&P 500 index over that stretch. Let's break down the technicals on Broadcom's chart and identify key price levels worth watching out for. After plumbing a seven-month low in early April, Broadcom shares have trended sharply higher within a rising wedge, with the price testing the pattern's upper trendline in recent trading sessions. However, profit-taking crept into the stock Thursday on the highest volume in around two months, which set the stage for today's selling. It's also worth pointing out that the relative strength index recently climbed above 80, a reading that coincided with major tops in the stock in December and June last year. Let's identify key support levels on Broadcom's chart to watch amid the potential for further selling and also locate an important overhead area worth monitoring during recovery efforts in the stock. Coming into Friday's session, the $250 level found a confluence of support from the rising wedge pattern's lower trendline and three notable peaks that formed on the chart between December and January. With the stock closing below this level, shares could test the next lower level of support at $235. Investors may look for dip buying opportunities in this region near the February countertrend peak. Further selling could trigger a steeper drop to the psychological $200 area. The shares would likely encounter support in this location near the upward sloping 50-day moving average, which also closely aligns with the January swing low and a period on consolidation in mid-March. During recovery efforts in Broadcom shares, investors should monitor the $265 area. Tactical traders who buy earnings-driven weakness may decide to lock in profits near the stock's all-time high toward the rising wedge pattern's peak. The comments, opinions, and analyses expressed on Investopedia are for informational purposes only. Read our warranty and liability disclaimer for more info. As of the date this article was written, the author does not own any of the above securities. Read the original article on Investopedia
Yahoo
an hour ago
- Yahoo
Why Is Byrna (BYRN) Stock Rocketing Higher Today
Shares of non-lethal weapons company Byrna (NASDAQ:BYRN) jumped 20.5% in the afternoon session after the company reported strong preliminary Q2 2025 results, with sales expected to be roughly $28.5 million, representing a 41% increase from $20.3 million in the fiscal second quarter of 2024. The promising result was attributed to strong early demand for the new Byrna Compact Launcher (CL), which launched on May 1, along with meaningful channel expansion. The shares closed the day at $31.34, up 18% from previous close. Is now the time to buy Byrna? Access our full analysis report here, it's free. Byrna's shares are extremely volatile and have had 71 moves greater than 5% over the last year. But moves this big are rare even for Byrna and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 10 days ago when the stock gained 5.9% after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. Byrna is up 11.2% since the beginning of the year, and at $31.50 per share, it is trading close to its 52-week high of $34.19 from February 2025. Investors who bought $1,000 worth of Byrna's shares 5 years ago would now be looking at an investment worth $5,212. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why Samsara (IOT) Shares Are Plunging Today
Shares of internet of Things company Samsara (NYSE:IOT) fell 5.1% in the afternoon session after the company reported mixed first quarter 2025 (fiscal 2026) results with billings falling below expectations. The weakness was also evident in its slower sales forecast, which indicates a noticeable decline from the better growth rate it just delivered. On the other hand, Samsara provided optimistic EPS guidance for the next quarter, which beat analysts' expectations. In addition, its EBITDA outperformed Wall Street's estimates by a wide margin. Overall, we think this was a mixed yet weaker quarter. The shares closed the day at $45.10, down 4.8% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Samsara? Access our full analysis report here, it's free. Samsara's shares are very volatile and have had 21 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 9 months ago when the stock gained 17.2% on the news that the company reported a "beat and raise" quarter. Samsara beat analysts' revenue, adjusted operating income, and EPS expectations this quarter. Notably, the top line grew by 37% year on year, benefiting from expansion from existing customers and new business wins. Looking ahead, it raised its full-year guidance for revenue, adjusted operating income, and EPS. Overall, this was a splendid quarter. Samsara is up 1.8% since the beginning of the year, but at $44.78 per share, it is still trading 26.5% below its 52-week high of $60.96 from February 2025. Investors who bought $1,000 worth of Samsara's shares at the IPO in December 2021 would now be looking at an investment worth $1,813. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
